Literature DB >> 17576741

Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients.

M García-Carrasco1, C Galarza, M Gómez-Ponce, R Cervera, J Rojas-Rodríguez, G Espinosa, S Bucciarelli, J A Gómez-Puerta, A Bové, R O Escárcega, J Font.   

Abstract

The objective of this study was to analyse the prevalence and characteristics of the main clinical and immunological manifestations at the onset and during the evolution of the disease in a cohort of patients from Latin America (mainly of mestizo origin) and to compare the Latin American with the European patients. Clinical and serological characteristics of 100 APS patients from Mexico and Ecuador were collected in a protocol form that was identical to that used to study the ;Euro-Phospholipid' cohort. The cohort consisted of 93 female patients (93.0%) and seven (7.0%) male patients. There were 91 mestizos (91.0%), seven whites (7.0%) and two Amerindians (2.0%). The most common manifestations were livedo reticularis (40.0%), migraine (35.0%), inferior extremity deep vein thrombosis (32.0%), thrombocytopenia (28.0%) and hemolytic anemia (20.0%). Several clinical manifestations were more prevalent in Latin American than in European patients and they included mainly neurological (migraine, transient global amnesia, acute ischemic encephalopathy, amaurosis fugax) and cutaneous (livedo reticularis, skin ulcerations, superficial cutaneous necrosis, multiple subungual splinter hemorrhages) manifestations as well as hemolytic anemia. The APS has a wide variety of clinical and immunological manifestations at the onset and during the evolution of the disease and the ethnic origin in addition to environmental and socioeconomic factors can modify the disease expression.

Entities:  

Mesh:

Year:  2007        PMID: 17576741     DOI: 10.1177/0961203307077108

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

Review 1.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

2.  The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Authors:  Ozan Unlu; Doruk Erkan; Medha Barbhaiya; Danieli Andrade; Iana Nascimento; Renata Rosa; Alessandra Banzato; Vittorio Pengo; Amaia Ugarte; Maria Gerosa; Lanlan Ji; Maria Efthymiou; D Ware Branch; Guilherme Ramires de Jesus; Angela Tincani; H Michael Belmont; Paul R Fortin; Michelle Petri; Esther Rodriguez; Guillermo J Pons-Estel; Jason S Knight; Tatsuya Atsumi; Rohan Willis; Stephane Zuily; Maria G Tektonidou
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-01       Impact factor: 4.794

Review 3.  Clinical implications of systemic lupus erythematosus without and with antiphospholipid syndrome in peri- and postmenopausal age.

Authors:  Bogna Grygiel-Górniak; Nattakarn Limphaibool; Mariusz Puszczewicz
Journal:  Prz Menopauzalny       Date:  2018-06-30

Review 4.  Epidemiology of Antiphospholipid Syndrome in the General Population.

Authors:  Jesse Y Dabit; Maria O Valenzuela-Almada; Sebastian Vallejo-Ramos; Alí Duarte-García
Journal:  Curr Rheumatol Rep       Date:  2022-01-05       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.